197 related articles for article (PubMed ID: 35104810)
1. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.
Ren Z; Zhang A; Sun Z; Liang Y; Ye J; Qiao J; Li B; Fu YX
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104810
[TBL] [Abstract][Full Text] [Related]
2. A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells.
Holcomb EA; Zou W
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104808
[TBL] [Abstract][Full Text] [Related]
3. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
4. Conditional Deletion of
Raghavan S; Tovbis-Shifrin N; Kochel C; Sawant A; Mello M; Sathe M; Blumenschein W; Muise ES; Chackerian A; Pinheiro EM; Rosahl TW; Luche H; de Waal Malefyt R
Front Immunol; 2021; 12():752348. PubMed ID: 34912335
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
6. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
8. PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and target tumor cells within the tumor.
Ambler R; Edmunds GL; Tan SL; Cirillo S; Pernes JI; Ruan X; Huete-Carrasco J; Wong CCW; Lu J; Ward J; Toti G; Hedges AJ; Dovedi SJ; Murphy RF; Morgan DJ; Wülfing C
Sci Signal; 2020 Sep; 13(649):. PubMed ID: 32934075
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
10. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8
Zou Z; Shen J; Xue D; Li H; Xu L; Cao W; Wang W; Fu YX; Peng H
Nat Commun; 2024 Jun; 15(1):4701. PubMed ID: 38830882
[TBL] [Abstract][Full Text] [Related]
12. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Martínez-Usatorre A; Donda A; Zehn D; Romero P
J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
[TBL] [Abstract][Full Text] [Related]
13. Th9 cells are subjected to PD-1/PD-L1-mediated inhibition and are capable of promoting CD8 T cell expansion through IL-9R in colorectal cancer.
Wang C; Lu Y; Chen L; Gao T; Yang Q; Zhu C; Chen Y
Int Immunopharmacol; 2020 Jan; 78():106019. PubMed ID: 31776089
[TBL] [Abstract][Full Text] [Related]
14. Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.
Arranz-Nicolás J; Martin-Salgado M; Rodríguez-Rodríguez C; Liébana R; Moreno-Ortiz MC; Leitner J; Steinberger P; Ávila-Flores A; Merida I
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33246984
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
16. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
17. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Sakuishi K; Apetoh L; Sullivan JM; Blazar BR; Kuchroo VK; Anderson AC
J Exp Med; 2010 Sep; 207(10):2187-94. PubMed ID: 20819927
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
[TBL] [Abstract][Full Text] [Related]
19. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
20. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
Schmid D; Park CG; Hartl CA; Subedi N; Cartwright AN; Puerto RB; Zheng Y; Maiarana J; Freeman GJ; Wucherpfennig KW; Irvine DJ; Goldberg MS
Nat Commun; 2017 Nov; 8(1):1747. PubMed ID: 29170511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]